세계 월경전증후군(PMS) 치료 시장 규모는 2024년 14억 4,300만 달러에 달했습니다. 향후 IMARC Group은 시장이 2033년까지 19억 2,000만 달러에 달해 2025년부터 2033년까지 3.2%의 연평균 성장률(CAGR)을 보일 것으로 예상하고 있습니다. 이 시장을 이끄는 요인으로는 환자 결과와 치료 효율을 높이는 정밀의료에 대한 관심 증가, 의료 접근성을 개선하고 치료 옵션을 확대하는 의료비 지출 증가, 여성의 노동력 진입 증가 등이 있습니다.
정밀의료에 대한 관심 증가
IMARC Group의 보고서에 따르면, 세계 정밀의료 시장은 2023년 752억 달러에 달할 것으로 예상됩니다. 정밀의료는 유전자 프로파일, 호르몬 상태, 증상 등 환자의 특성에 맞춰 의료적 개입을 할 수 있습니다. PMS의 경우, 증상과 중증도는 개인에 따라 매우 다양하기 때문에 개인별 맞춤 접근을 통해 보다 효과적인 치료를 할 수 있습니다. 또한, PMS와 관련된 유전적 요인과 바이오마커는 환자별로 가장 효과적인 치료법을 조정하는 데 도움이 됩니다. 그 결과, 치료 성적이 향상되고 치료법의 시행착오가 줄어듭니다. 이와는 별개로 환자의 유전자 및 생리적 프로파일에 따라 치료법을 매칭하여 부작용이 적은 약물을 선택하는 것이 시장의 성장을 확대하고 있습니다.
의료비 지출 증가
의료비 지출이 증가함에 따라 PMS로 고통받는 여성을 포함한 더 많은 사람들이 PMS를 적절히 진단하고 치료할 수 있는 일차의료 의사나 산부인과 의사 등 의료기관을 찾게 되었습니다. 또한, 높은 의료비 지출은 호르몬 요법, 항우울제 등의 약물 치료, 인지행동치료, 생활습관 개선 등의 비약물 치료 등 PMS의 다른 치료법에 대한 접근성이 높은 것과도 관련이 있습니다. 높은 의료비 지출은 더 나은 PMS 치료법을 찾는 데 도움이 되는 연구 개발 활동의 기회를 늘리고 있습니다. 메디케어-메디케이드 서비스센터 웹사이트에 2024년 업데이트된 내용에 따르면, GDP 대비 의료비 비중은 2022년 17.3%에서 2032년 19.7%로 확대될 것으로 예측됩니다.
여성의 노동 참여 증가
세계은행에 따르면, 2023년 여성 노동력 비율은 전 세계적으로 49%를 기록했습니다. 더 많은 여성들이 노동 인구에 진입함에 따라 PMS의 경제적 영향은 더욱 분명해지고 있습니다. 이 증상은 생산성, 출석률, 직장 내 성과를 위협할 수 있습니다. 이러한 영향을 인식한 고용주와 의료 서비스 제공자들은 PMS로 인한 직장 내 혼란을 줄일 수 있는 효과적인 치료법을 찾으려는 노력을 기울이고 있습니다. 또한, 기업들은 PMS와 같은 생식기 건강 문제에 대한 지원을 포함한 직장 내 웰빙 프로그램에 투자하고 있습니다. 이러한 프로그램은 치료 접근성, 증상이 있는 날에 대한 유연한 스케줄 조정, 교육적 자원 등을 제공하며, 이 모든 것이 PMS 치료에 대한 인식과 이용률을 높이는 데 도움이 됩니다.
The global premenstrual syndrome treatment market size reached USD 1,443 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,920 Million by 2033, exhibiting a growth rate (CAGR) of 3.2% during 2025-2033. The market is driven by the growing focus on precision medicine, as it enhances patient outcomes and treatment efficiency, rising healthcare spending, which improves access to care and expands treatment options, and increasing female workforce participation.
Growing focus on precision medicine
As per the IMARC Group's report, the global precision medicine market reached US$ 75.2 Billion in 2023. Precision medicine can deliver medical interventions that are tailored as per patient characteristics including genetic profile, hormone status, and symptoms. In the context of PMS, it can vary widely in terms of symptoms and severity among individuals, personalized approaches allow for more targeted and effective treatments. Furthermore, genetic factors or biomarkers that are linked to PMS help in tailoring treatment options to be most effective for each patient. This is leading to improved outcomes and lesser trial and error in treatment options. Apart from this, by selecting medications that are less likely to cause an adverse reaction by matching patients with treatments based on their genetic or physiological profiles is expanding the market growth.
Rising healthcare spending
As healthcare expenditure is increasing, more people, including women troubled with PMS, are able to seek medical help, including primary care physicians, gynecologists and other practitioners who may diagnose and treat PMS appropriately. In addition, high healthcare spending often found to be associated with higher access to other treatment options of PMS, which includes pharmacological treatment like hormonal therapies, antidepressants, and non-pharmacological therapies like cognitive behavioral therapy or lifestyle modifications. High healthcare expenditure is creating more opportunities for R&D activities that can help find better PMS therapies. According to the content updated in 2024 on the website of the Centers for Medicare & Medicaid Services, the healthcare spending share of GDP is forecasted to grow from 17.3% in 2022 to 19.7% in 2032.
Increasing female workforce participation
As per the World Bank, female labor force participation rates were 49% worldwide in 2023. As more women are entering the workforce, the economic implications of PMS are becoming more apparent. This poses a threat to productivity, attendance and performance at work due to its symptoms. Recognizing these impacts, employers and healthcare providers are more motivated to find effective treatments that can help reduce the workplace disruptions caused by PMS. In addition, companies are investing in workplace wellness programs that include support for reproductive health issues like PMS. These programs offer access to therapies, flexible scheduling around symptomatic days, and educational resources, all of which increase awareness and use of available PMS treatments.
Analgesics accounts for the majority of the market share
Premenstrual syndrome refers to several symptoms that are physical and psychological in nature and which affect many women prior to menstrual cycles, such as abdominal pain, headaches, and muscular pain. Analgesics are widely preferred as they provide quick relief from these symptoms, making them a go-to choose for many women looking immediate comfort during their menstrual cycles. In addition, people are getting aware about their efficiency in controlling pain, which is driving the demand for analgesics in the PMS treatment market.
Over-the-counter holds the largest share of the industry
Over-the-counter (OTC) products for PMS include pain relievers, diuretics, and other supplements like calcium and magnesium that one can be purchased on the counter without the prescription of doctor. This accessibility allows women treat symptoms independently without having to see a doctor. Bloating, cramping, fatigue, and mood swings are becoming serious problems as a result of PMS. OTC medicines offer numerous solutions to these issues as per different symptoms. The familiarity of OTC brands and the ease of purchasing these products from pharmacies, retail stores, and online platforms is contributing to the market growth.
Drugs stores and retail pharmacies represent the leading market segment
Women are preferring drug stores and pharmacies as they can get a wide range of OTC medications and supplements to alleviate PMS symptoms. This ensures that those women suffering from PMS can get relief in the quickest way possible without the need for a prescription. . Secondly, drug stores and retail pharmacies offer customers a wide diversity of brands and forms of products which can help them select the required products according to their needs and symptoms. This variety enhances individual satisfaction and ensures that people can find products tailored as per their specific needs.
North America leads the market, accounting for the largest premenstrual syndrome treatment market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for premenstrual syndrome treatment.
As per an article published on the website of Canadian Institute for Health Information, Canada health care spending reached $344 billion in 2023. As healthcare expenditures is rising, there is a corresponding increase in the availability of specialized healthcare services and resources dedicated to the health of women, including PMS. This includes improved access to healthcare professionals who can diagnose and treat PMS effectively, leading to greater awareness and recognition of the condition among patients. Moreover, North America has a high prevalence of PMS cases, which prompts a significant demand for effective treatment solutions. In addition, the strong economy of the region, leading to the greater affordability of healthcare services and medications, further driving the market growth.
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)